AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9850)・商品コード:DATA904C9850
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819, a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP); and AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. It has partnership with other pharmaceutical companies for the development of proteomics and non-systemic therapeutic biologics. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.

AzurRx BioPharma Inc (AZRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AzurRx BioPharma Raises USD0.64 Million in Financing 10
Licensing Agreements 11
Azurrx Biopharma Enters into Licensing Agreement with Transchem 11
AzurRx BioPharma Enters into Licensing Agreement with TransChem 12
Equity Offering 13
AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13
AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14
AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15
AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16
AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17
Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18
AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19
AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20
AzurRx BioPharma Raises USD5.3 Million in IPO 21
Debt Offering 23
AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23
AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24
Acquisition 25
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25
AzurRx BioPharma Inc – Key Competitors 27
AzurRx BioPharma Inc – Key Employees 28
AzurRx BioPharma Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Corporate Communications 30
Oct 16, 2017: AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors 30
Sep 25, 2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer 31
Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 32
Clinical Trials 33
Apr 18, 2018: AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AzurRx BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AzurRx BioPharma Raises USD0.64 Million in Financing 10
Azurrx Biopharma Enters into Licensing Agreement with Transchem 11
AzurRx BioPharma Enters into Licensing Agreement with TransChem 12
AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13
AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14
AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15
AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16
AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17
Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18
AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19
AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20
AzurRx BioPharma Raises USD5.3 Million in IPO 21
AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23
AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25
AzurRx BioPharma Inc, Key Competitors 27
AzurRx BioPharma Inc, Key Employees 28
AzurRx BioPharma Inc, Subsidiaries 29

List of Figures
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9850)販売に関する免責事項を必ずご確認ください。
★調査レポート[AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆